key: cord-0989649-7w19xxlq authors: Sacramento, Carolina Q.; Fintelman-Rodrigues, Natalia; Temerozo, Jairo R.; de Paula Dias Da Silva, Aline; da Silva Gomes Dias, Suelen; dos Santos da Silva, Carine; Ferreira, André C.; Mattos, Mayara; Pão, Camila R. R.; de Freitas, Caroline S.; Soares, Vinicius Cardoso; Hoelz, Lucas Villas Bôas; Fernandes, Tácio Vinício Amorim; Branco, Frederico Silva Castelo; Bastos, Mônica Macedo; Boechat, Núbia; Saraiva, Felipe B.; Ferreira, Marcelo Alves; Rajoli, Rajith K. R.; Pedrosa, Carolina S. G.; Vitória, Gabriela; Souza, Letícia R. Q.; Goto-Silva, Livia; Guimarães, Marilia Zaluar; Rehen, Stevens K.; Owen, Andrew; Bozza, Fernando A.; Bou-Habib, Dumith Chequer; Bozza, Patrícia T.; Souza, Thiago Moreno L. title: The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2 date: 2020-10-16 journal: bioRxiv DOI: 10.1101/2020.06.15.153411 sha: 97f1c14187fcf2976ce1c897f54b5a9af3ebbf72 doc_id: 989649 cord_uid: 7w19xxlq Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven overwhelmingly successful and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Daclatasvir (DCV) and sofosbuvir (SFV) are clinically approved against hepatitis C virus (HCV), with satisfactory safety profile. DCV and SFV target the HCV enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited the production of infectious SARS-CoV-2 in Vero cells, in the hepatoma cell line (HuH-7) and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than DCV, SFV and its nucleoside metabolite inhibited replication in Calu-3 cells. Moreover, SFV/DCV combination (1:0.15 ratio) inhibited SARS-CoV-2 with EC50 of 0.7:0.1 μM in Calu-3 cells. SFV and DCV prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Both drugs inhibited independent events during RNA synthesis and this was particularly the case for DCV, which also targeted secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial DCV in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Doses higher than those approved may ultimately be required, but these data provide a basis to further explore these agents as COVID-19 antiviral candidates. *Correspondence footnote: 39 Thiago Moreno L. Souza, PhD 40 *********************************** with EC50 values ranging between 0.6 to 1.1 µM, without statistical distinction (Table 1) . DCV showed limited antiviral activity when viral RNA copies/mL in the culture supernatant 157 fraction (Figures S2) was utilized, suggesting a mechanism unrelated to RNA production. than by viral RNA quantification in the supernatant fraction ( Figure S2 ). DCV was at least 163 7-times more potent than SFV in HuH-7 and Calu-3 cells (Table 1) . SFV's nucleoside metabolite (GS-331007) was also tested for anti-SARS-CoV-2 165 activity. GS-331007 was inactive in Vero cells and less active than SFV in Huh-7 cells 166 ( Figure 1 and Table 1 ). Curiously, in respiratory cells, GS-331007 presented a moderate anti-167 SARS-CoV-2 activity, similar to that of SFV ( Figure 1 and Table 1 ). Given that SARS-CoV-2 replication in Calu-3 cells appeared to be more sensitive to 169 antiviral activity, this cell line was used to assess the combination of SFV and DCV. SFV/DCV combination was used at a ratio of 1:0.15 ratio, in accordance with its dose ratio 171 for HCV-positive patients (400 mg SFV plus 60 mg DCV). In this assessment of the 172 interaction, the potency of SFV increased 10-fold in the presence of suboptimal DCV 173 concentrations ( Figure 1C and E and Table 1 ). DCV was demonstrated to be 1. (Table 1) . None of the studied drugs were more potent than RDV ( Figure 179 1 and Table 1 ). These data demonstrate that SARS-CoV-2 is susceptible to DCV and SFV in vitro, 181 with a higher potency demonstrated for DCV. The COVID-19 pandemic continues to present a major concern to global health, and is The total viral RNA from a culture supernatants and/or monolayers was extracted using Twelve independent fields were evaluated from duplicate wells per experimental condition. (((...) ) )))))..))))......))))))))))).(((...))).. ....... ((((......) ))... (((((.....) ))))((( ((.......)))))..))))))((. (((((..(((...) ) )..))))))) Origin and evolution of pathogenic coronaviruses An interactive web-based dashboard to track COVID-19 in real time. 613 The Lancet Infectious Diseases WHO R&D Blueprint: informal consultation on prioritization of candidate 615 therapeutic agents for use in novel coronavirus 2019 infection Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With 620 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized 621 Clinical Trial Remdesivir in adults with severe COVID-19: 624 a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet A Trial of Lopinavir-Ritonavir in Adults 627 Hospitalized with Severe Covid-19 Remdesivir for 5 or 10 629 Days in Patients with Severe Covid-19 Remdesivir for the 632 Treatment of Covid-19 -Preliminary Report Approved Antiviral Drugs over the Past 50 Years Daclatasvir: A NS5A Replication Complex Inhibitor for 637 A SARS-CoV-2-639 Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-640 Sofosbuvir: a review of its use in patients with chronic hepatitis C Yellow fever 644 virus is susceptible to sofosbuvir both in vitro and in vivo 647 Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus 648 replication Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term 651 sequelae The 653 clinically approved antiviral drug sofosbuvir inhibits Zika virus replication SOVALDI (sofosbuvir) Tissue expression of CTSA -Staining in lung -The Human Protein Atlas Tissue expression of CES1 -Summary -The Human Protein Atlas Tissue expression of HINT1 -Summary -The Human Protein Atlas Remdesivir is a 665 direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute 666 respiratory syndrome coronavirus 2 with high potency Nucleotide Analogues as Inhibitors of Viral 669 Polymerases Sofosbuvir protects 671 human brain organoids against SARS-CoV-2 Central nervous system manifestations of COVID-19: A systematic 674 review Clinical course and risk factors for mortality of 676 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet MolDock: a new technique for high-accuracy molecular 679 docking RNA genome 681 conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look. 682 RNA Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations 685 Derived from their Established Human Pharmacokinetics Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and 689 Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive 690 Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial 691 Agents Concerns 693 about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the 694 new therapeutic area of COVID-19 infection A 697 rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and 698 development: IUPHAR Review 29 An interactive web-based dashboard to track COVID-19 in real time. 700 The Lancet Infectious Diseases Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a 702 review of immune changes in patients with viral pneumonia SARS-CoV-2 and viral sepsis: observations and 705 hypotheses SARS-CoV-2 infection of the liver directly 707 contributes to hepatic impairment in patients with COVID-19 Coronavirus puts drug repurposing on the fast track 712 Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled 713 trial in Brazil (SOFFA study) Remdesivir 716 Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 The nucleoside 719 analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture 720 and experimental cat infection studies Advantages of the Parent Nucleoside GS-441524 over Remdesivir for 723 Covid-19 Treatment HCV drugs sofosbuvir, daclatasvir show promise as potential COVID-19 treatment Zika virus 729 impairs growth in human neurospheres and brain organoids Virological 735 assessment of hospitalized patients with COVID-2019 An improved model to predict 739 physiologically based model parameters and their inter-individual variability from 740 anthropometry Reference values for total blood volume and cardiac output in humans Comparison of 745 human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and 746 correlation with permeability of 26 drugs Prediction of human intestinal first-pass 749 metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Physiologically based pharmacokinetic modelling 2: predicting the 752 tissue distribution of acids, very weak bases, neutrals and zwitterions Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 757 and Drug Transporters Experimental execution and analysis RKRR 764 Data analysis, manuscript preparation and revision TMLS 766 Conceptualized the experiments -CQS, NFR, JRT, TMLS 767 Study coordination -TMLS